A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.
Condition or disease
This will be a dose-escalating study. ABI-007 will be administered as an outpatient infusion for three weeks followed by a week of rest. The treatment course will repeat every 28 days. No pretreatment will normally be considered necessary. Patients will have white blood cell and platelet counts monitored as will indications of performance (Karnofsky Performance Status), and will be asked to describe adverse events, if present. Patients will be treated for a minimum of two cycles to be evaluable for the study, and may continue in the study for four cycles within the study, if tumor response and safety parameters warrant continuing. Patients may continue on study medication beyond this at the investigator's discretion.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
At least 18 years of age
Life expectancy of at least 2 months
Off all therapy for at least 3 weeks prior to study drug administration
Biopsy-proven diagnosis of advanced malignancy
Patients with solid tumors who have failed standard therapy
Karnofsky Performance Status of 70% or 0-2 SWOG Performance Status
Hemoglobin at least 9
White Blood Cell count of at least 3000/mm3 with absolute neutrophil count of at least 1500/mm3
Platelet count of at least 100,000/mm3
Serum Creatinine less than 2 mg/dL
Transaminases less than 3X the upper limit of normal